These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33488968)

  • 1. Design, Synthesis, and Biological Evaluation of IRAK4-Targeting PROTACs.
    Chen Y; Ning Y; Bai G; Tong L; Zhang T; Zhou J; Zhang H; Xie H; Ding J; Duan W
    ACS Med Chem Lett; 2021 Jan; 12(1):82-87. PubMed ID: 33488968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma.
    Chen Y; Bai G; Ning Y; Cai S; Zhang T; Song P; Zhou J; Duan W; Ding J; Xie H; Zhang H
    Eur J Med Chem; 2020 Mar; 190():112092. PubMed ID: 32014679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and pharmacological evaluation of 2,3-dihydrobenzofuran IRAK4 inhibitors for the treatment of diffuse large B-cell lymphoma.
    Chen Y; Ning Y; Chen Z; Xue Y; Wu Q; Duan W; Ding J; Zhou J; Xie H; Zhang H
    Eur J Med Chem; 2023 Aug; 256():115453. PubMed ID: 37163947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of LC-MI-3: A Potent and Orally Bioavailable Degrader of Interleukin-1 Receptor-Associated Kinase 4 for the Treatment of Inflammatory Diseases.
    Chen L; Luo R; Ma L; Xu Y; Cao J; Jiang Z; Chen S; Huang X; Zhang M; Zheng L; Zhang Y; Yin L; Yu J; Zheng X; Zheng L; Huang P; Liang G
    J Med Chem; 2024 May; 67(10):8060-8076. PubMed ID: 38722184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation.
    Zhang J; Fu L; Shen B; Liu Y; Wang W; Cai X; Kong L; Yan Y; Meng R; Zhang Z; Chen YP; Liu Q; Wan ZK; Zhou T; Wang X; Gavine P; Del Rosario A; Ahn K; Philippar U; Attar R; Yang J; Xu Y; Edwards JP; Dai X
    Cell Chem Biol; 2020 Dec; 27(12):1500-1509.e13. PubMed ID: 32888499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting IRAK4 for Degradation with PROTACs.
    Nunes J; McGonagle GA; Eden J; Kiritharan G; Touzet M; Lewell X; Emery J; Eidam H; Harling JD; Anderson NA
    ACS Med Chem Lett; 2019 Jul; 10(7):1081-1085. PubMed ID: 31312412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of dysfunction of human variants of the IRAK4 kinase and a role for its kinase activity in interleukin-1 receptor signaling.
    De S; Karim F; Kiessu E; Cushing L; Lin LL; Ghandil P; Hoarau C; Casanova JL; Puel A; Rao VR
    J Biol Chem; 2018 Sep; 293(39):15208-15220. PubMed ID: 30115681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.
    Kelly PN; Romero DL; Yang Y; Shaffer AL; Chaudhary D; Robinson S; Miao W; Rui L; Westlin WF; Kapeller R; Staudt LM
    J Exp Med; 2015 Dec; 212(13):2189-201. PubMed ID: 26621451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors.
    Guidetti F; Arribas AJ; Sartori G; Spriano F; Barnabei L; Tarantelli C; Von Roemeling R; Martinez E; Zucca E; Bertoni F
    J Clin Med; 2023 Jan; 12(2):. PubMed ID: 36675328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenically active MYD88 mutations in human lymphoma.
    Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
    Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88
    Scott JS; Degorce SL; Anjum R; Culshaw J; Davies RDM; Davies NL; Dillman KS; Dowling JE; Drew L; Ferguson AD; Groombridge SD; Halsall CT; Hudson JA; Lamont S; Lindsay NA; Marden SK; Mayo MF; Pease JE; Perkins DR; Pink JH; Robb GR; Rosen A; Shen M; McWhirter C; Wu D
    J Med Chem; 2017 Dec; 60(24):10071-10091. PubMed ID: 29172502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin 1/Toll-like receptor-induced autophosphorylation activates interleukin 1 receptor-associated kinase 4 and controls cytokine induction in a cell type-specific manner.
    Cushing L; Stochaj W; Siegel M; Czerwinski R; Dower K; Wright Q; Hirschfield M; Casanova JL; Picard C; Puel A; Lin LL; Rao VR
    J Biol Chem; 2014 Apr; 289(15):10865-10875. PubMed ID: 24567333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cloning and functional characterization of IRAK4 in large yellow croaker (Larimichthys crocea) that associates with MyD88 but impairs NF-κB activation.
    Zou PF; Huang XN; Yao CL; Sun QX; Li Y; Zhu Q; Yu ZX; Fan ZJ
    Fish Shellfish Immunol; 2017 Apr; 63():452-464. PubMed ID: 27989863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a Series of 5-Azaquinazolines as Orally Efficacious IRAK4 Inhibitors Targeting MyD88
    Degorce SL; Anjum R; Bloecher A; Carbajo RJ; Dillman KS; Drew L; Halsall CT; Lenz EM; Lindsay NA; Mayo MF; Pink JH; Robb GR; Rosen A; Scott JS; Xue Y
    J Med Chem; 2019 Nov; 62(21):9918-9930. PubMed ID: 31622099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune Diseases.
    Zheng X; Ji N; Campbell V; Slavin A; Zhu X; Chen D; Rong H; Enerson B; Mayo M; Sharma K; Browne CM; Klaus CR; Li H; Massa G; McDonald AA; Shi Y; Sintchak M; Skouras S; Walther DM; Yuan K; Zhang Y; Kelleher J; Liu G; Luo X; Mainolfi N; Weiss MM
    J Med Chem; 2024 Oct; 67(20):18022-18037. PubMed ID: 39151120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4.
    Degorce SL; Anjum R; Dillman KS; Drew L; Groombridge SD; Halsall CT; Lenz EM; Lindsay NA; Mayo MF; Pink JH; Robb GR; Scott JS; Stokes S; Xue Y
    Bioorg Med Chem; 2018 Feb; 26(4):913-924. PubMed ID: 29398441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IRAK4 in TLR/IL-1R signaling: possible clinical applications.
    Li X
    Eur J Immunol; 2008 Mar; 38(3):614-8. PubMed ID: 18286571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional assessment of the mutational effects of human IRAK4 and MyD88 genes.
    Yamamoto T; Tsutsumi N; Tochio H; Ohnishi H; Kubota K; Kato Z; Shirakawa M; Kondo N
    Mol Immunol; 2014 Mar; 58(1):66-76. PubMed ID: 24316379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TPL2 enforces RAS-induced inflammatory signaling and is activated by point mutations.
    Dodhiawala PB; Khurana N; Zhang D; Cheng Y; Li L; Wei Q; Seehra K; Jiang H; Grierson PM; Wang-Gillam A; Lim KH
    J Clin Invest; 2020 Sep; 130(9):4771-4790. PubMed ID: 32573499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IRAK4 kinase activity controls Toll-like receptor-induced inflammation through the transcription factor IRF5 in primary human monocytes.
    Cushing L; Winkler A; Jelinsky SA; Lee K; Korver W; Hawtin R; Rao VR; Fleming M; Lin LL
    J Biol Chem; 2017 Nov; 292(45):18689-18698. PubMed ID: 28924041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.